Serogroup B meningococcal disease during Hajj: Preparing for the worst scenario

Mohamed K.M. Khalil; Raymond Borrow

doi:10.1016/j.tmaid.2009.07.001

Serogroup B meningococcal disease during Hajj: Preparing for the worst scenario

Mohamed K.M. Khalil
, Raymond Borrow^*

^*Corresponding author for this work

Manchester Meningococcal Reference Unit General

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

The Islamic Hajj pilgrimage to Mecca, Saudi Arabia has historically been associated with outbreaks of serogroup A and W135 meningococcal disease. Prevention against meningococcal disease has principally been vaccination with meningococcal polysaccharide vaccines, either in a bivalent serogroup A/C or quadrivalent A/C/Y/W135 form. These interventions have suppressed meningococcal disease since 2002. Countries with large Muslim populations have now started to show a trend of increased serogroup B meningococcal disease, a serogroup for which there is no universal vaccine available. These trends should increase our preparedness to expect a sudden change in the etiology of meningococcal disease during the Hajj.

Original language	English
Pages (from-to)	231-234
Number of pages	4
Journal	Travel Medicine and Infectious Disease
Volume	7
Issue number	4
DOIs	https://doi.org/10.1016/j.tmaid.2009.07.001
Publication status	Published - Jul 2009

Bibliographical note

Funding Information:
Dr R Borrow has received assistance to attend scientific meetings from Wyeth, Novartis, Sanofi Pasteur and Baxter Bioscience and has served as an ad hoc consultant for Wyeth, GlaxoSmithKline, Novartis, Sanofi Pasteur and Baxter Bioscience. Industry honoraria received for consulting, lecturing and writing are paid directly into Central Manchester and Manchester Children's University Hospitals NHS Trust endowment fund. Dr Borrow has performed contract research on behalf of the Health Protection Agency (funded by Wyeth, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Alexion Pharmaceuticals Inc, Emergent Europe and Merck).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Hajj
Meningococcal
Pilgrimage
Serogroup B
Vaccine

Access to Document

10.1016/j.tmaid.2009.07.001

Cite this

@article{9d01d3d9c06645b2a808ea05b4b5b9f3,

title = "Serogroup B meningococcal disease during Hajj: Preparing for the worst scenario",

abstract = "The Islamic Hajj pilgrimage to Mecca, Saudi Arabia has historically been associated with outbreaks of serogroup A and W135 meningococcal disease. Prevention against meningococcal disease has principally been vaccination with meningococcal polysaccharide vaccines, either in a bivalent serogroup A/C or quadrivalent A/C/Y/W135 form. These interventions have suppressed meningococcal disease since 2002. Countries with large Muslim populations have now started to show a trend of increased serogroup B meningococcal disease, a serogroup for which there is no universal vaccine available. These trends should increase our preparedness to expect a sudden change in the etiology of meningococcal disease during the Hajj.",

keywords = "Hajj, Meningococcal, Pilgrimage, Serogroup B, Vaccine",

author = "Khalil, \{Mohamed K.M.\} and Raymond Borrow",

note = "Funding Information: Dr R Borrow has received assistance to attend scientific meetings from Wyeth, Novartis, Sanofi Pasteur and Baxter Bioscience and has served as an ad hoc consultant for Wyeth, GlaxoSmithKline, Novartis, Sanofi Pasteur and Baxter Bioscience. Industry honoraria received for consulting, lecturing and writing are paid directly into Central Manchester and Manchester Children's University Hospitals NHS Trust endowment fund. Dr Borrow has performed contract research on behalf of the Health Protection Agency (funded by Wyeth, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Alexion Pharmaceuticals Inc, Emergent Europe and Merck). ",

year = "2009",

month = jul,

doi = "10.1016/j.tmaid.2009.07.001",

language = "English",

volume = "7",

pages = "231--234",

journal = "Travel Medicine and Infectious Disease",

issn = "1477-8939",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Serogroup B meningococcal disease during Hajj

T2 - Preparing for the worst scenario

AU - Khalil, Mohamed K.M.

AU - Borrow, Raymond

N1 - Funding Information: Dr R Borrow has received assistance to attend scientific meetings from Wyeth, Novartis, Sanofi Pasteur and Baxter Bioscience and has served as an ad hoc consultant for Wyeth, GlaxoSmithKline, Novartis, Sanofi Pasteur and Baxter Bioscience. Industry honoraria received for consulting, lecturing and writing are paid directly into Central Manchester and Manchester Children's University Hospitals NHS Trust endowment fund. Dr Borrow has performed contract research on behalf of the Health Protection Agency (funded by Wyeth, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Alexion Pharmaceuticals Inc, Emergent Europe and Merck).

PY - 2009/7

Y1 - 2009/7

N2 - The Islamic Hajj pilgrimage to Mecca, Saudi Arabia has historically been associated with outbreaks of serogroup A and W135 meningococcal disease. Prevention against meningococcal disease has principally been vaccination with meningococcal polysaccharide vaccines, either in a bivalent serogroup A/C or quadrivalent A/C/Y/W135 form. These interventions have suppressed meningococcal disease since 2002. Countries with large Muslim populations have now started to show a trend of increased serogroup B meningococcal disease, a serogroup for which there is no universal vaccine available. These trends should increase our preparedness to expect a sudden change in the etiology of meningococcal disease during the Hajj.

AB - The Islamic Hajj pilgrimage to Mecca, Saudi Arabia has historically been associated with outbreaks of serogroup A and W135 meningococcal disease. Prevention against meningococcal disease has principally been vaccination with meningococcal polysaccharide vaccines, either in a bivalent serogroup A/C or quadrivalent A/C/Y/W135 form. These interventions have suppressed meningococcal disease since 2002. Countries with large Muslim populations have now started to show a trend of increased serogroup B meningococcal disease, a serogroup for which there is no universal vaccine available. These trends should increase our preparedness to expect a sudden change in the etiology of meningococcal disease during the Hajj.

KW - Hajj

KW - Meningococcal

KW - Pilgrimage

KW - Serogroup B

KW - Vaccine

UR - https://www.scopus.com/pages/publications/69249205416

U2 - 10.1016/j.tmaid.2009.07.001

DO - 10.1016/j.tmaid.2009.07.001

M3 - Article

C2 - 19717106

AN - SCOPUS:69249205416

SN - 1477-8939

VL - 7

SP - 231

EP - 234

JO - Travel Medicine and Infectious Disease

JF - Travel Medicine and Infectious Disease

IS - 4

ER -

Serogroup B meningococcal disease during Hajj: Preparing for the worst scenario

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this